Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects

Liver International

Volumn 34, Issue 4, 2014, Pages 604-611

  Kim, Nam Hoon ^a   Kim, Joo Hyung ^a   Kim, Yoon Jung ^a   Yoo, Hye Jin ^a   Kim, Hee Young ^a   Seo, Ji A ^a   Kim, Nan Hee ^a   Choi, Kyung Mook ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Kim, Sin Gon ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Hypertriglyceridaemia; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonobese; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; KOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; YOUNG ADULT;

HYPERTRIGLYCERIDAEMIA; METABOLIC SYNDROME; NONALCOHOLIC FATTY LIVER DISEASE; NONOBESE; WEIGHT LOSS;

ADIPOSITY; ADULT; BODY MASS INDEX; FATTY LIVER; HUMANS; LONGITUDINAL STUDIES; REGRESSION ANALYSIS; REPUBLIC OF KOREA; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84895799127     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12454     Document Type: Article

References (33)

1. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-61.
2. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
4. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-43.
5. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
6. Park SH, Kim BI, Kim SH, et al. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. J Am Coll Nutr 2007; 26: 321-6.
7. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-9.
8. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.
9. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
10. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-7.
11. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
12. Park SH, Kim BI, Kim HJ, et al. Clinical features associated with improvement of fatty liver disease. Intern Med J 2005; 35: 473-7.
13. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.
14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
15. Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169-75.
16. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40: 745-52.
17. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-61.
18. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098-105.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
20. Force IOT. The Asian-Pacific perspective: Redefining Obesity and Its Treatment. Sydney, Australia: Health Communications Australia Pty Limited on behalf of the Steering Committee, 2000.
21. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-6.
22. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
23. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330: 932.
24. Kim HK, Park JY, Lee KU, et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci 2009; 337: 98-102.
25. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
26. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
27. Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011; 93: 1048-52.
28. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-87.
29. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
30. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 424-31.
31. Tsuneto A, Hida A, Sera N, et al. Fatty liver incidence and predictive variables. Hypertens Res 2010; 33: 638-43.
32. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-25 e6.
33. Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-95.